Business
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction
Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Lab...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n\n\n\n Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly\n \n $1 Billion\n \n\n\n\n\n MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management!\n \n\n Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures\n \n\n\n\n Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders\n \n\n\n\n Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting\n \n\n\n\n Sends Letter to MediPharm Shareholders and Files Proxy Circular\n \n\n\n\n\n TORONTO, ON\n \n\n ,\n \n\n May 8, 2025\n \n\n /CNW/ -- Apollo Technology Capital Corporation (\"Apollo\"), which together with its affiliates and associates collectively is one of the largest shareholders of MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\", or the \"Company\"), owning approximately 3.0% of the Company's common stock, today filed a dissident information proxy circular (the \"Circular\") in connection with its intention to nominate six highly qualified director candidates to MediPharm's Board of Directors (the \"Board\") at the Company's upcoming 2025 Annual and Special Meeting of Shareholders to be held on\n \n\n June 10, 2025\n \n\n (the \"Annual Meeting\").\n \n\n\n\n\n\n\n\n\n In connection with the Circular and nominations, Apollo sent a letter to its fellow shareholders urging them to hold MediPharm's Board accountable for overseeing years of underperformance, failed operational strategies, outrageous com...